You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 65 PD-L1 by RNA next generation sequencing: comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Biomarkers, immune monitoring, and novel technologies
65 PD-L1 by RNA next generation sequencing: comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020311019
Dec 20203003
Jan 20215208
Feb 20211204
Mar 20213807
Apr 20213707
May 2021402
Jun 2021009
Jul 20211012
Aug 20210013
Sep 2021005
Oct 202142022
Nov 202157019
Dec 20212001
Jan 20222402
Feb 20223208
Mar 20227005
Apr 202210204
May 20224204
Jun 20226503
Jul 20225807
Aug 20226408
Sep 20224402
Oct 20226604
Nov 20223803
Dec 20226603
Jan 20235602
Feb 20236401
Mar 20235202
Apr 20232805
May 20234405
Jun 20233201
Jul 202356015
Aug 20236203
Sep 20239202
Oct 20234802
Nov 20234003
Dec 20234801
Jan 20241600
Feb 20243800
Mar 20245001
Apr 20245802
May 20243203
Jun 20245201
Jul 20243800
Aug 20242201
Sep 20242202
Oct 20242403
Nov 20242602
Dec 20242003
Jan 20252804
Feb 20251408
Mar 2025005
Apr 2025002
May 2025004
Jun 2025002
Total23370269